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Summary 
Regulated adhesion enables T cells to migrate through tissue and transiently interact with an 
endless succession of cells. Monoclonal antibody (mAb) engagement of the CD3/T cell receptor 
(TCR) complex results in a rapid and transient augmentation of the adhesion function of LFA-1 
and VLA integrin molecules on human T cells. We show in this study that mAb crosslinking 
of the  T  cell-specific  accessory molecules  CD7  and  CD28,  or  treatment with  the  Ca  2+ 
ionophore A23187, results in the rapid induction of integrin-mediated adhesion to three distinct 
ligands: the extracellular matrix protein fibronectin, and the cell surface molecules ICAM-1 and 
VCAM-1. Like CD3 crosslinking,  increased adhesion via CD7 and CD28 crosslinking appears 
to involve both protein kinase C (PKC) and cAMP-dependent protein kinases. In contrast, A23187 
induction of adhesion is unaffected by PKC inhibitors.  CD7 is preferentially expressed on naive 
T cells and is unique in being a potent inducer of  naive  T cell adhesion. Enhanced expression/function 
of adhesion-inducing molecules thus overcomes relative deficits in adhesion receptor expression. 
"[  mphocytes express a multitude of cell surface receptors 
.1_r  that are capable of mediating adhesion to other cells and 
proteins (1, 2). Regulation of the functional activity of these 
adhesion molecules is critical to both T cell migration and 
recognition, since T cells must transiently interact with cells 
and proteins found in the extracellular environment. One im- 
portant element in the regulation of adhesion is the rapid 
increase in the adhesive function of integrin molecules that 
occurs after crosslinking of the CD3/TCR complex by mAb 
(3-6) or foreign antigen (7). Integrins mediate T cell adhe- 
sion to other cells via interactions such as LFA-1 binding to 
its  ligands ICAM-1  and ICAM-2,  and VLA-4 binding to 
VCAM-1, and also to extraceUular matrix (ECM)  1 compo- 
nents via interactions such as VLA-4 and VLA-5 to fibronectin 
(FN) (1, 2, 8). Activation of other lymphoid cell types by 
mAb crosslinking of functionally relevant cell surface mole- 
cules also results in increased  LFA-l-dependent adhesion. Such 
molecules include HLA class II (9) and CD14 (10) on mono- 
cytes, and surface  immunoglobulin (11), CD19 (12), and CD40 
(13) on B cells. These results suggest that increased adhesion 
via integrin molecules represents one of the earliest responses 
of lymphoid cells to the delivery of various activation signals. 
1Abbreviations used in  this paper." ECM,  extracellular  matrix;  FN, 
fibronectin;  HSA, human serum albumin. 
We reasoned that the functional activity of integrin mole- 
cules on human T cells might also be increased  by mAb cross- 
linking of other molecules besides the CD3/TCR.  In this 
study we report the ability of three different activation signals 
to increase integrin-mediated adhesion: the Ca  2  + ionophore 
A23187, and mAb crosslinking of the CD7 and CD28 mol- 
ecules, both of which have been implicated as T cell activa- 
tion molecules (14-16). These activation  signals can coor- 
dinately increase T cell adhesion to three different ligands: 
the LFA-1 ligand ICAM-1,  the VLA-4 endothelial cell sur- 
face ligand VCAM-1, and the VLA-4 and VLA-5 ligand FN. 
We demonstrate similarities in the biochemical signals gener- 
ated by CD3, CDT, and CD28 crosslinking that distinguish 
receptor-mediated activation from the effects of A23187. The 
differential expression of CD7 on functionally important T 
ceil subsets suggests unique functional roles for these mole- 
cules in regulating T  cell adhesion. 
Materials and Methods 
Human  T  Cells.  CD4 + T cells were isolated by negative  mag- 
netic immunosdection as previously described (4,  17). Briefly, 
PBMC were  isolated  from either leukapheresis  packs or buffy  coats 
by Ficoll-Hypaque  density-gradient  centrifugation.  Resting CD4 + 
T cells were subsequently  isolated from PBMC using Advanced 
Magnetic Particles (Advanced  Magnetics, Inc., Cambridge, MA), 
577  The Journal of Experimental  Medicine  ￿9 Volume 175  February  1992  577-582 Dynabeads (Dynal, Inc., Great Neck, NY), and a cocktail of mAbs 
consisting of: HLA class II mAb IVA12, CD19 mAb FMC63, CD16 
mAb 3G8, CD11b mAb NIHllb-1, CD14 mAb 63D3, CD8 mAb 
B9.8.4, and antigiycophorin  mAb 10F7. CD4+CD45RA ~ naive 
T  cells and CD4+CD45RO + memory T  cells were isolated by 
adding the CD45RA mAb G1-15 (to negatively isolate memory 
T cells) or the CD45RO mAb UCHL1 (to negatively isolate naive 
T cells) to the mAb cocktail. The T cell populations were >99% 
CD3 § and >96% CD4 §  Naive and memory T cell purity was 
>95%  as determined  by flow cytometric  analysis. 
Antibodies and Other  Reagents.  The following mAbs were used 
as purified Ig:  CD3 mAb OKT3,  CD7 mAb 3A1, CD5 mAb 
OKT1, CD58 mAb TS2/9 (all American Type Culture Collection, 
Kockville, MD), CD2 mAb 95-5-49. The following mAbs were 
used as dilutions of ascites fluids: HLA class II mAb IVA12, CD14 
mAb 63D3, CD28 mAb OKT10, anti-glycophorin mAb 10F7 (all 
ATCC), CD19 mAb FMC63 (Dr. H. Zoh, Flinders Medical Centre, 
Bedford Park, Australia), CD16 mAb 3G8 (Dr. D. Segal, National 
Cancer Institute, Bethesda, MD), CDllb mAb NIH11b-1 (18), CD8 
mAb B9.8.4 (Dr. B. Malissen, Centre d'immunologie de MarseiUe- 
Luminy, Marseilles, France), CD45RA mAb G1-15, and CD28 mAb 
9.3  (Dr. J. Ledbetter;  Oncogen, Seattle, WA),  CD45RO mAb 
UCHL1 (Dr. P. Beverley, Imperial Cancer Research Fund, London, 
UK), CD43 mAb 84-3C1, CD26 mAb 5/9, CD59 mAb BRIC 
229 (Dr. D. Anstee, Southwest Regional Blood Transfusion Centre, 
Bristol, UK). E2-specific mAb TU12 (A. Ziegler, Institute  of Ex- 
perimental  Immunology,  Tubingen,  Germany),  and GD-3 mAb 
C281 (Dr. D. Cheresh,  Scripps Clinic, La Jolla,  CA). 
ICAM-1 was purified by affinity chromatography from the Reed- 
Sternberg cell line L428 as previously described (19). Recombinant, 
soluble VCAM-1 was isolated from the culture supernatants of Chi- 
nese hamster ovary cells expressing a truncated  form of the full- 
length VCAM-1 cDNA as previously described (20, 21). Human 
FN was obtained from the New York Blood Center. Cytochalasin 
B was purchased from Sigma Chemical Co. (St. Louis, MO), and 
staurosporin  was purchased  from  Boehringer  Mannheim  Diag- 
nostics, Inc. (Indianapolis, IN). Both were dissolved in DMSO be- 
fore use. Dibutyryl cAMP (Calbiochem-Behring Corp., San Diego, 
CA) was dissolved in PBS before use. The Ca  2+ ionophore A23187 
(Sigma Chemical Co.) was dissolved in ethanol. 
Adhesion Assays.  Adhesion assays were performed as described 
(4). Briefly, 96-well microtiter plates (Costar Data Packaging Corp., 
Cambridge, MA) were incubated overnight at 4~  with the indi- 
cated concentrations of FN, ICAM-1, or VCAM-1, and unbound 
binding sites subsequently blocked with PBS/2.5% BSA. Each well 
contained 50,000 SlCr-labeled T cells in a final volume of 0.1 ml 
PBS/0.5% human serum albumin (HSA). For A23187 activation, 
cells were added to wells containing  1 ~g/ml A23187. For PMA 
activation,  cells were added to wells containing  10 ng/ml PMA 
(Sigma Chemical Co.): For CD3, CD7, and CD28 activation, T 
cells were incubated.With'10~#g/tnl of purified rhAb, or a 1:5,000. 
dilution  of ascites~162  30 tftin,at:AC~, washed twice, and added to  . 
wells  ~o~aiqiag, O.5--17~//fi~. goat anti-trmuse  lff (O/ganbn 
Teknika,,~l'alXe~yfi, PA~. ~~,Lh  settting at.~C; plai:eg we're-rap- 
~dl~ .W..~d to 37~C.fof lomb, nonadhe~ent.selrs trashed og 
arafet~'-percentage  of, bb~nd'cd!s .was det~nined by tysiag the 
well contents  with detergent  and cou~atiftg 3' emissions. All data 
are expressed as the mean percent of cells biading 'from three repli- 
cate wells plus SEM. 
Flow  Microfluorometry  Staining  and flow cytometric analysis was 
performed as previously described (22) using sequential incubations 
with: saturating concentrations of test mAb; Texas red-labeled anti- 
Ig sandwich; irrelevant excess IgG to block free sites on bound 
sandwich; and CD45RA mAb Leu-18-FITC (Becton Dickinson 
and Co.,  Mountain  View, CA).  Logarithmic  amplification was 
provided by a three-decade logarithmic  amplifier. 
Results and Discussion 
Multiple Activation Signals Upregulate T  Cell Adhesion to 
VCAM-1, FN, and ICAM-I.  We and others have previously 
shown that the phorbol ester PMA, mitogenic pairs of CD2 
mAbs, or mAb crosslinking of the CD3/TCR results within 
minutes in increased adhesion via LFA-1 to ICAM-1 (3, 5, 
6),  via the VLA integrins  VLA-4 and VLA-5 to FN,  and 
via VLA-6 to LN (4, 5). The data in Fig. 1 show that three 
additional activation signals can similarly increase integrin- 
mediated adhesion:  the Ca  2+ ionophore A23187, and mAb 
crosslinking of the T cell-specific molecules CD7 and CD28. 
In addition to increasing T cell adhesion to FN and ICAM-1 
(Fig.  1 B), A23187,  CD7,  and CD28 crosslinking  also in- 
crease  adhesion to the VLA-4 ligand VCAM-1 (Fig.  I  A), 
extending our earlier findings on VCAM-1 adhesion using 
PMA activation  (21,  23).  These results  suggest  that  these 
activation signals act coordinately on multiple T  cell inte- 
grins,  enabling T  cells to adhere to a variety of cell surface 
and ECM ligands, mAb blocking studies demonstrated that 
adhesion to these ligands after activation occurs via the ex- 
pected integrin  receptors (data not  shown). 
The percentage of calls binding after CD7 crosslinking is 
generally similar in magnitude to that induced by CD3 cross- 
linking. In contrast, CD28-mediated activation often results 
in the adhesion of fewer cells (Fig.  1 A and Fig. 2) and shows 
more donor-dependent variation in magnitude than does CD3- 
or CD7-mediated activation (data not shown). Crosslinking 
of T cell surface molecules by mAb is not a general stimulus 
for increasing adhesion since mAb crosslinking of 12 other 
cell surface molecules expressed on resting  CD4 +  T  cells 
fails to increase T  cell adhesion  to FN  (Fig.  1 B  and data 
not  shown). 
Signalling Pathways  Involved in A23187-, CD7-, and CD28- 
mediated Induction oJ Adhesion.  Studies in a variety of systems 
have shown that adhesive interactions involving the integrin 
family of adhesion molecules require an intact cytoskeleton 
(24). The data in Fig. 2 A  also show that increased integrin 
function induced by the various activation stimuli can all be 
inhibited by treatment of T  cells with the cytoskeleton dis- 
rupting agent cytochalasin B, further illustrating the impor- 
tance of the cytosk_eleton  to these activation-dependent  changes 
in adhesion. 
- Activation of'PKC b~' the phorbol ester PMA appears to 
be sufficient on its own tcr induce imegrin-mediated  adhe- 
sion (Fig. 2) 0-5, 23)'; and PKC has been implicated in in- 
duction of adhesion via CD3/TCK  crosslinking  (3).  Fur- 
thermore, activation of cAMl~dependent protein kinases may 
play a negative regulatory role in adhesion, since treatment 
of T  cells with dibutyryl cAMP has been shown to inhibit 
CD3-mediated activation of LFA-1 (3). To assess the signaling 
pathways involved in these newly described modes of inducing 
T cell adhesion, we have analyzed the ability of PKC inhibi- 
tors and dibutyryl cAMP to inhibit adhesion to FN induced 
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Figure  1.  Multiple activation stimuli rapidly increase CD4 + T  cell 
adhesion  to VCAM-I, FN, and ICAM-1. (A) Binding of 51Cr-labeled 
CD4 * T cells to purified VCAM-1  (applied at the indicated concentra- 
tions) after no activation (U]), or after activation for 10 mip- at 37~  (11) 
with one of the following stimuli (as indicated):  1 #g/ml A23187, the 
CD3 mAb OKT3 crosslinked by goat anti-mouse Ig (GAMIg), the CD7 
mAb 3A1 crosslinked by GAMIg, and the CD28 mAb 9.3 crosslinked 
by GAMIg. (B) Binding of 51Cr-labeled T cells to FN (left) or purified 
ICAM-1 (right) after coating of T cells with mAbs specific for the indi- 
cated molecules in the presence (solid bars) or absence (shaded bars) of 0.5 
#g/ml GAMIg. Purified FN was applied at 1/~g/well and purified ICAM-1 
was applied at 3 ng/weU. Data are representative of a minimum of three 
experiments with three different  donors. 
by each of these modes of activation. First, as previously de- 
scribed,  incubation  of  T  cells  with  the  PKC  inhibitor 
staurosporin was  shown  to completely inhibit T  cell adhe- 
sion induced by PMA (Fig. 2 B). In contrast to earlier results 
(3), CD3-mediated activation of binding was also completely 
inhibited by staurosporin.  Both CD7-  and CD28-mediated 
activation of adhesion also appear to involve the PKC pathway, 
since staurosporin completely inhibits  adhesion induced by 
these  stimuli.  In  contrast,  A23187-mediated  activation  is 
unaffected by the same concentrations of staurosporin,  indi- 
cating that:  the concentration  of staurosporin used was not 
generally inhibitory;  and  the changes  in intracellular Ca 2+ 
caused by A23187 that lead to increased adhesion appear not 
to require PKC activation. These results suggest that A23187- 
induced adhesion may involve a biochemical mechanism dis- 
tinct  from  the  other  modes  of activation. 
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Figure  2.  Effects of cytochalasin  B,  the  protein kinase  C  inhibitor 
staurosporin, and dibutyryl cAMP on CD4 + T cell adhesion  to FN in- 
duced by the indicated activation stimuli. Binding was assessed as described 
in Materials and Methods.  For cytochalasin B (top) and dibutyryl cAMP 
(bottom), T cells were preincubated with inhibitor for 20 rain at 37~ 
In all experiments,  inhibitor was present  throughout the adhesion assay. 
Open bars indicate adhesion in the absence of inhibitor, solid bars indicate 
adhesion in the presence of inhibitor, and crosshatched bars indicate adhe- 
sion in the presence of an equivalent amount of DMSO. Dibutyryl cAMP 
was dissolved in PBS. Cytochalasin B was used at a final concentration 
of 5 #g/ml, staurosporin at 1 #M, and dibutyryl cAMP at 3 mM. FN 
was applied at 1 #g/well. Data shown are representative  of a minimum 
of three experiments with different donors.  Results  shown reflect inde- 
pendent experiments done on different  days with different  donors. 
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Figure 3.  Differential expression of CD7 on CD4 + CD45A § naive T 
cell and CD4+CD45RO § memory T cells. Naive T cells are represented 
by a solid line and memory cells by a dashed line. Staining of both popula- 
tions with negative control mAb is comparable,  and the naive pattern is 
shown (dotted line). Results  shown are for two donors whose cells have 
been extensively characterized for differential expression of multiple cell 
surface molecules (data not shown).  Median expression of CD7 was 1.5- 
fold higher on naive cells than memory cells for donor 1308, and 2.1-fold 
higher for donor 1210. Test mAb used were CD7 mAb 3A1, and CD3 
mAb OKT3. 
579  Shimizu et al. Elevation of cAMP levels in T cells using dibutyryl cAMP 
was also shown to dramatically inhibit adhesion induced via 
CD3,  CD7,  and CD28 (Fig.  2 C). There was no effect on 
PMA-mediated activation of adhesion, as previously reported 
(3). Partial but consistent inhibition by dibutyryl cAMP of 
A23187-mediated induction of adhesion was also observed. 
The simplest interpretation  of these findings is that at least 
two pathways of regulation are available, one of which is in- 
hibited by cAMP, and the other by staurosporin.  Although 
sufficient signal (i.e., A23187 or PMA) via either is enough 
on its own to induce adhesion,  weaker cooperative signals 
via both pathways may be activated by CD3, CD7, and CD28. 
Preferential Expression of CD7  on  CD4 §  Naive  T  Cells. 
Peripheral T cells are a heterogeneous mix of phenotypically 
distinct subsets that migrate, adhere,  and respond differently 
(25, 26). Two major subsets of CD4 + T  cells functionally 
designated as naive and memory T cells can be identified by 
differential expression of isoforms of the CD45 molecule (22). 
There is generally concordant increased expression of a number 
of adhesion molecules on memory T cells, including a one- 
to twofold greater expression of LFA-1 and a three- to four- 
fold greater expression of VLA-4, VLA-5, and VLA-6 (4, 5, 
22). Phenotypic analysis by two-color flow cytometry shows 
that in contrast to integrin expression, CD7 is expressed at 
1.5-2.6-fold  higher  levels  on  CD4 +  naive  T  cells  than 
memory cells (Fig.  3). Greater CD7 expression on naive T 
cells than memory cells is also unique when compared with 
other molecules involved in regulating integrin function, such 
as CD2 and CD28 (5,  22) (data not shown).  CD3 expres- 
sion is compared with CD7 in Fig. 3 because: of the fore- 
going molecules, CD3 is the only one that  has greater ex- 
pression on naive cells than memory cells (rather consistently 
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Figure 4.  CD7 crosslinking results in comparable adhesion of CD4 + 
naive  and  memory  T  cells  to  FN  and  ICAM-1.  Binding  of purified 
CD4 § CD45RA § naive (solid bars) and CD4 +  CD4RO + memory (shaded 
bars) human CD4 § T  cells to FN (left) and ICAM-1 (right)  after the in- 
dicated activation stimulus was assessed.  FN was applied at 1 #g/ml and 
ICAM-1 was applied at 1.5 ng/well. Results are shown for a representa- 
tive donor with differential adhesion of naive and memory cells to inte- 
grin ligands after PMA- and CD3-mediated activation as previously de- 
scribed (4,  5). 
1.2-fold higher);  and CD3- and CD7-mediated augmenta- 
tion  of adhesion  is compared below. 
Regulation of Differential Naive and Memory T Cell Adhesion 
by Differential Expression of  Adhesion-inducing Molecules.  Greater 
expression on memory compared with naive T cells is gener- 
ally  associated  with  greater  binding  of memory  cells  to 
ICAM-1, FN, and laminin using the previously described ac- 
tivation stimuli (PMA,  CD3 crosslinking,  and CD2 pairs) 
(4, 5). CD28 crosslinking similarly induces preferential adhe- 
sion of memory T  cells from the donor shown in Fig.  4, 
and the majority of other donors' cells tested (data not shown). 
In contrast, each of five donors' cells tested showed naive T 
cell adhesion to integrin ligands at a level equal to or greater 
than comparable memory T cells after CD7 crosslinking (Fig. 
4 and data not shown). Thus, CD7 may be particularly crit- 
ical in regulating integrin function on naive T cells,  consis- 
tent with its modest preferential expression on those cells. 
Our results demonstrate that, despite lower integrin expres- 
sion on naive T  cells,  the adhesiveness  of naive T  cells can 
be efficiently induced by a compensatory mechanism of greater 
expression/function of adhesion-inducing molecules such as 
CD7. 
In summary,  the present studies demonstrate that T  cell 
adhesion is regulated not only by CD3/TCR  engagement 
but also by engagement of two other cell surface molecules, 
CD7 and CD28.  Both CD7 and CD28 are T  cell-specific 
molecules that have been demonstrated to facilitate  T cell ac- 
tivation (14,  16), and thus might be expected to play some 
role in modulating T cell-adhesive interactions.  Recent studies 
have shown that the molecule B7/BB-1 on activated B cells 
is a ligand for CD28 (27). We have not observed induction 
of adhesion with  a soluble B7-Ig fusion protein  (28),  but 
this could be due to the very low affinity of the B7 fusion 
protein for CD28 on resting human T  cells compared with 
the CD28-specific mAb used in this study (Y. Shimizu and 
P. Linsley, unpublished observations). We are currently using 
B7 + cell transfectants to address this issue further.  While a 
ligand for CD7 has not been identified,  CD7 is one of the 
earliest T  cell-specific markers in the thymus  (29, 30).  Its 
absence has been reported in one case of severe combined im- 
munodeficiency (31),  and CD7 mAb crosslinking has been 
reported to induce changes in intracellular  Ca  2+ (15), as well 
as enhancing  T  cell proliferation  (14). 
The physiologic role of CD7 and CD28 in upregulation 
of T cell adhesion remains undefined.  Since more is known 
about CD28, it is easiest  to speculate on its potential role. 
For example, initial contact between a T and a B cell bearing 
the relevant antigen would result not only in augmented T 
cell adhesion due to CD3/TCR engagement, but also in in- 
duction of B cell B7 expression due to the engagement  of 
MHC class II (32).  Subsequent interaction between T  cell 
CD28 and B cell B7 would result in activation via CD28 
and longer cell-cell contact, ultimately resulting in functional 
responses  such  as  cytokine production,  proliferation,  and 
differentiation. This model implicates CD28 in modulating 
the duration of the adhesive interactions accompanying TCR 
engagement.  This is supported by preliminary findings that 
580  CD7 and CD28  Crosslinking Modulates T  Cell Adhesion co-crosslinking of either CD7 or CD28 with CD3 results 
in prolongation of the transient adhesion via integrins in- 
duced by CD3 alone (E. Ennis and Y. Shimizu, unpublished 
observations). Alternatively, it is possible that CD7 and CD28 
may sometimes modulate adhesion independently of CD3 
engagement or preceding that engagement. This would re- 
quire the ligand to be expressed  on the apposing cell prior 
to T cell contact, as would occur with previously activated 
B cells, activated monocytes, or certain thymic stromal cells 
(32-34). Progress in understanding CD7 will depend on defini- 
tion of its natural ligands. We would expect that a CD7 ligand, 
which remains to be defined, is also expressed on a function- 
ally unique cell type that is efficient in antigen presentation. 
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